MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD – Get Free Report) shares fell 14.1% during mid-day trading on Wednesday . The stock traded as low as $1.14 and last traded at $1.16. 109,107 shares were traded during trading, a decline of 19% from the average session volume of 134,123 shares. The stock had previously closed at $1.35.
MyMD Pharmaceuticals Stock Down 14.1 %
The company’s 50 day moving average price is $1.47 and its 200 day moving average price is $1.74.
MyMD Pharmaceuticals Company Profile
MyMD Pharmaceuticals, Inc, a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression.
Recommended Stories
- Five stocks we like better than MyMD Pharmaceuticals
- What does consumer price index measure?
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- 3 Healthcare Dividend Stocks to Buy
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Stock Average Calculator
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for MyMD Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyMD Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.